Check the method being used for Sterility. It should be USP 71, 72, or 73. Bioburden, PCR, and Microarray are not USP approved for injectables, and are not sufficient. Those methods are better suited for topicals, supplements, tinctures, etc.

White people with social media accounts be getting mad as hell when i mention that I'm Partially European, that i share the same Ancestry with them and they still get mad when I explain it to them, about a thing, getting a DNA TEST through AncestryDNA or 23andMe, they forget that the human civilization is a Technologically-advanced civilization, we have Technology that can reveal information about a human's ethnicity that's passed down to them from both of their parents, the Technology (Microarray Technology) that's been in development since the 1980s (The Digital Age) and debuted in the 1990s @neiltyson

Important note for clients submitting injectable samples: Microarray and PCR-based screens are not USP <71> sterility tests, and they are not recognized as compendial sterility methods under USP <71>, <72>, or <73>. USP <71>, <72>, and <73> remain the official compendial sterility tests for injectable products. Rapid or molecular methods may have research or screening value, but they should not be represented as USP sterility testing unless they fully meet the applicable USP compendial requirements and validation expectations. Always ask the lab: “Is this a true USP compendial sterility test (<71/72/73>), or a non-compendial rapid method?” Your compliance depends on clear answers. #USP #SterilityTesting #PharmaQC

This study, a continuation of the previous study using the same cohort, performed microarray analysis of penile skin biopsies on 26 PFS patients and 26 controls. 1,446 genes were sign. overexpressed and 2,318 sign. underexpressed in the PFS patients. 67/n sciencedirect.com/science/ar…

5/Finding 2: Over two decades, peripheral techniques turned over almost completely (RNA-seq, CRISPR, ChIP-seq replacing PCR, microarray, Northern blot), while a core stayed put. The field re-tooled its bench without broadening it. ⬇️

How do you feel about the new microarray types of tests like from Vibrant Labs?

It is TMA (tissue microarray) Tuesday at the CHTN! Today, we are promoting our CHTN_OvCa2 - Ovarian Carcinoma Survey TMA. More details on our TMA website: ow.ly/TMxq50Z88O9 #cooperativehumantissuenetwork #tissuemicroarray #TMA #biorepository #ovariancancer

I had a prenatal diagnosis for my son and the microarray didn’t get back until week 25. I chose life, but if I would have chosen to terminate.. I wouldn’t have broadcasted. If you are struggling, join a support group, there are tons for these situations. 🤷🏻‍♀️

Children received comprehensive genomic analysis encompassing chromosomal microarray, Fragile X testing and exome sequencing in a clinically accredited laboratory. 44/153 (29%) had a genetic diagnostic result encompassing monogenic conditions (n = 35) and CNVs (n = 9).

Everyone, I made a major discovery today! 🧬🧬🧬 I figured out how to create a digital DNA sequencer to analyze for specific gene mutations. All that is needed: cheek cell sample for DNA smart phone camera free access to online genomic databases and healthy reference controls python script for creating a digital microarray (which I already have) python script for creating a coordinate mapping layer that translates physical image data into a biological index of specific genes (which I already have) total cost = $0

Rapid #genome sequencing identifies a greater number of unique diagnoses in infants with #CongenitalHeartDisease compared with chromosomal microarray analyses. thecardiologyadvisor.com/new…

🧬✨ New insights in congenital heart disease genetics! A recent study highlights the growing role of rapid genome sequencing (rGS) in infants with congenital heart defects (CHD) — the most common birth defect worldwide ❤️‍🩹 🔍 Key findings: ▪️ Genetic testing was performed in 77.7% of infants with CHD ▪️ Overall diagnostic yield: ~27% ▪️ rGS showed a comparable (and slightly higher) yield vs microarray (16.9% vs 14.3%) ▪️ rGS identified 44% more unique genetic diagnoses ▪️ Faster turnaround (~5 days) → crucial for neonatal decision-making 📊 Importantly, rGS is emerging as a first-line test, offering: ✔️ Broader detection (CNVs single nucleotide variants) ✔️ Improved clinical insight ✔️ Potential impact on management & family counselling 💡 This study reinforces the need for integrating genomics into routine CHD care, especially in critically ill infants. 📄 Based on: 🚀 Take-home message: Genomics is no longer the future — it’s already reshaping how we diagnose and manage congenital heart disease. #CongenitalHeartDisease #Genomics #PrecisionMedicine #PediatricCardiology #CardioGenetics #rGS #RareDisease #Neonatology #AHA #MedicalResearch #GeneticTesting 🧬💙

قیمت کلاس های خصوصی مجموعه ترانسکریپتومیکس ( RNA-SEQ, Microarray ) ۶ میلیون WES ۱۲ میلیون به صورت گروهی ۳ میلیون WES ۷ میلیون

دوستان من دوره های بیوانفورماتیک برگزار میکنیم با این موضوعات RNA -seq WES Meta-analysis Network analysis Microarray اگه دانشجو هستید تو رشته های سلولی مولکولی ، علوم آزمایشگاهی ، ژنتیک و ... میخواید با یادگیری این تکنیک ها رزومه درست کند دوره رو شرکت کنید

Pro-lifers have been saying that prenatal tests for Down syndrome are often inaccurate That’s only the initial screening. Once you take the further test it’s basically guaranteed. From ChatGPT: “Amniocentesis with a full chromosome analysis (karyotype or chromosomal microarray): the false-positive rate for Down syndrome is effectively close to 0%. Laboratories generally report accuracy above 99.9%, and a clear finding of trisomy 21 is considered definitive.” Don’t fall for their nonsense.

📑 Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray #OpenAccess #LiverX journals.lww.com/hepcomm/ful…

No amount of TPUs run on the PDB or 23andMe microarray readouts will solve this, period. [Hot take: neither will perturb-seq on cell lines for the vast majority of druggable targets. more on this in an upcoming Substack on sequencing and translation.] @yusufroohani:

9) The authors included an independent cohort with 32 LC patients, but it looks like they used a different measurement for it: a microarray with 118 autoantigens. Here, LC patients had increased antibodies against several complement components.

3) Next, they searched for the targets of the antibodies using the HuProt™ microarray which includes over 21.000 different human proteins. Unfortunately, there wasn’t a clear difference in positive response to proteins between LC and convalescent controls